Related Experiment Video
Updated: May 10, 2026
07:46
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Europe's oncology industrial complex: size, components, and implications for value
Javier-David Benitez-Fuentes1, Dario Trapani2, Rodrigo Lastra Del Prado3
1Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; RIO Working Group, Zaragoza, Spain.
Journal of Cancer Policy
|May 8, 2026
Summary
Europe's oncology industrial complex faces challenges where increased spending doesn't guarantee patient benefit. Stewardship is needed to align cancer care funding with actual service capacity for better outcomes.
Area of Science:
- Health economics
- Oncology
- Health services research
Background:
- Europe's oncology industrial complex (OIC) integrates research, regulation, economic evaluation, and service delivery in public health systems.
- Cancer diagnosis and mortality remain high in the EU, with significant financial investment in oncology.
- Oncology medicine spending has surged, but growth doesn't automatically ensure patient benefit due to implementation constraints.
Purpose of the Study:
- To analyze the challenges within Europe's oncology industrial complex.
- To propose strategies for aligning healthcare expenditure with deliverable cancer care pathways.
- To advocate for improved patient outcomes through better stewardship of public investment.
Main Methods:
- Analysis of cancer costs and oncology medicine spending across European Union member states.
- Examination of real-world capacity constraints in cancer care implementation.
- Argument for policy interventions to enhance stewardship and outcome evaluation.
Main Results:
- Total cancer costs in Europe were €199 billion in 2018, with oncology medicine spending rising from €24.9 billion (2014) to €64.3 billion (2023).
- Spending increases are not directly correlated with patient benefit due to limitations in diagnostic and service capacity.
- Current spending growth does not automatically translate into improved patient survival or quality of life.
Conclusions:
- Effective stewardship is crucial to ensure public investment in cancer care yields measurable patient outcomes.
- Aligning reimbursement with diagnostic and service capacity is essential for implementation.
- Institutionalizing post-marketing evaluation and withdrawing low-value practices can optimize cancer care delivery.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...